Variant report
Variant | nsv573058 |
---|---|
Chromosome Location | chr16:76716423-76718625 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:0)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
No data |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs571935658 | chr16:76716426-76716427 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
2 | rs77468349 | chr16:76716433-76716434 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
3 | rs188479383 | chr16:76716509-76716510 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
4 | rs574146684 | chr16:76716563-76716564 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
5 | rs536793371 | chr16:76716607-76716608 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
6 | rs73616035 | chr16:76716628-76716629 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
7 | rs573338802 | chr16:76716658-76716659 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs191572458 | chr16:76716673-76716674 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs565114905 | chr16:76716717-76716718 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs577905671 | chr16:76716747-76716748 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs373801959 | chr16:76716771-76716772 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs367600910 | chr16:76716833-76716834 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs138695442 | chr16:76716843-76716844 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs372320486 | chr16:76716845-76716846 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
15 | rs141140405 | chr16:76716848-76716849 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs150385548 | chr16:76716858-76716859 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs551390685 | chr16:76716860-76716861 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs73616036 | chr16:76716905-76716906 | Flanking Active TSS Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs184204796 | chr16:76716907-76716908 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs571790919 | chr16:76716922-76716923 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs117027044 | chr16:76716930-76716931 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs79826027 | chr16:76716932-76716933 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
23 | rs536851868 | chr16:76716955-76716956 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs553577608 | chr16:76716958-76716959 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs188708022 | chr16:76716966-76716967 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs539121442 | chr16:76717026-76717027 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
27 | rs72788664 | chr16:76717061-76717062 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
28 | rs575547245 | chr16:76717158-76717159 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
29 | rs73616037 | chr16:76717159-76717160 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
30 | rs543142675 | chr16:76717204-76717205 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
31 | rs138069121 | chr16:76717206-76717207 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
32 | rs377042575 | chr16:76717207-76717208 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
33 | rs528490638 | chr16:76717210-76717211 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
34 | rs369293771 | chr16:76717213-76717214 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
35 | rs574345935 | chr16:76717243-76717244 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
36 | rs149516357 | chr16:76717252-76717253 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
37 | rs559105656 | chr16:76717253-76717254 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
38 | rs143991055 | chr16:76717278-76717279 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
39 | rs551625192 | chr16:76717324-76717325 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
40 | rs192770210 | chr16:76717346-76717347 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
41 | rs75420791 | chr16:76717374-76717375 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
42 | rs576237358 | chr16:76717390-76717391 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
43 | rs539047374 | chr16:76717392-76717393 | Active TSS Enhancers Flanking Active TSS | n/a | n/a | Overlapped CNVs | n/a |
44 | rs183525124 | chr16:76717431-76717432 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs531154280 | chr16:76717458-76717459 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs376204293 | chr16:76717459-76717460 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
47 | rs187061224 | chr16:76717530-76717531 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs567979587 | chr16:76717567-76717568 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
49 | rs550883365 | chr16:76717587-76717588 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
50 | rs114259542 | chr16:76717594-76717595 | Flanking Active TSS Enhancers | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Esophageal squamous carcinoma | 21637470 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Acute lymphoblastic leukemia | 17690704 | CNVD |
Autism | 19415332 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Non-syndromic sensorineural hearing loss | 22037309 | CNVD |
Schizophrenia | 22958593 | CNVD |
Breast cancer | 20668451 | CNVD |
Cancer | 20668451 | CNVD |
Lung cancer | 20668451 | CNVD |
Ovarian cancer | 20668451 | CNVD |
Pancreas cancer | 20668451 | CNVD |
Prostate cancer | 20668451 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Autism | 22495311 | CNVD |
Wilms tumour | 21544195 | CNVD |
Prostate cancer | 18632612 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Breast cancer | 17850661 | CNVD |
Breast cancer | 16702952 | CNVD |
Medulloblastoma | 16968546 | CNVD |
Prostate cancer | 19242612 | CNVD |
Cancer | 22429812 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Ewing''s sarcoma | 22429812 | CNVD |
Melanoma | 18172304 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Breast cancer | 20837533 | CNVD |
Breast cancer | 21264507 | CNVD |
Glioblastoma multiforme | 19960244 | CNVD |
Hepatocellular carcinoma | 22174799 | CNVD |
Multiple myeloma | 21628407 | CNVD |
Ovarian cancer | 22174824 | CNVD |
Breast cancer | 21858162 | CNVD |
Acute lymphoblastic leukemia | 20435627 | CNVD |
Ewing''s sarcoma | 17952124 | CNVD |
Breast cancer | 17001317 | CNVD |
Breast cancer | 17133270 | CNVD |
Acute lymphoblastic leukemia | 22237106 | CNVD |
Breast cancer | 17603634 | CNVD |
Prostate cancer | 16573809 | CNVD |
Prostate cancer | 17245344 | CNVD |
Basal cell lymphoma | 16317097 | CNVD |
Diffuse large b-cell lymphoma | 16317097 | CNVD |
Malignant peripheral nerve sheath tumor | 18522746 | CNVD |
Endometrioid adenocarcinoma | 16974079 | CNVD |
High-grade prostatic intraepithelial neoplasia | 16573809 | CNVD |
T-cell prolymphocytic leukemia | 17713554 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Medulloblastoma | 16783165 | CNVD |
Breast cancer | 21806811 | CNVD |
Ovarian clear cell carcinoma | 21343371 | CNVD |
Melanoma | 22183965 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Myelofibrosis | 22110671 | CNVD |
Poland''s syndrome | 22110015 | CNVD |
Neuroblastoma | 21899760 | CNVD |
Liver carcinoma | 19366792 | CNVD |
Prostate cancer | 21965145 | CNVD |
Cancer | 21183584 | CNVD |
Ovarian cancer | 20844748 | CNVD |
Lung cancer | 18438408 | CNVD |
Prostate cancer | 19156837 | CNVD |
Acute myeloid leukemia | 17377590 | CNVD |
Breast cancer | 20409316 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Breast cancer | 21509527 | CNVD |
Lung cancer | 24585490 | CNVD |
Neuroblastoma | 18923524 | CNVD |
Cancer | 20164920 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Breast cancer | 22522925 | CNVD |
Cancer | 20581869 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr16:76715600-76716600 | Weak transcription | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
2 | chr16:76716400-76716800 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
3 | chr16:76716400-76717800 | Enhancers | iPS-15b Cell Line | embryonic stem cell |
4 | chr16:76716600-76716800 | Enhancers | ES-I3 Cell Line | embryonic stem cell |
5 | chr16:76716600-76716800 | Enhancers | HUES6 Cell Line | embryonic stem cell |
6 | chr16:76716600-76717600 | Enhancers | H1 BMP4 Derived Mesendoderm Cultured Cells | ES cell derived |
7 | chr16:76716600-76717800 | Enhancers | HUES48 Cell Line | embryonic stem cell |
8 | chr16:76716600-76718000 | Enhancers | iPS-18 Cell Line | embryonic stem cell |
9 | chr16:76716600-76718600 | Enhancers | HUES64 Cell Line | embryonic stem cell |
10 | chr16:76716800-76717000 | Flanking Active TSS | ES-I3 Cell Line | embryonic stem cell |
11 | chr16:76716800-76717000 | Enhancers | H1 Cell Line | embryonic stem cell |
12 | chr16:76716800-76717000 | Flanking Active TSS | iPS-20b Cell Line | embryonic stem cell |
13 | chr16:76716800-76717200 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
14 | chr16:76716800-76717400 | Flanking Active TSS | HUES6 Cell Line | embryonic stem cell |
15 | chr16:76717000-76717400 | Active TSS | ES-I3 Cell Line | embryonic stem cell |
16 | chr16:76717000-76717400 | Active TSS | iPS-20b Cell Line | embryonic stem cell |
17 | chr16:76717400-76717600 | Flanking Active TSS | ES-I3 Cell Line | embryonic stem cell |
18 | chr16:76717400-76717600 | Enhancers | ES-WA7 Cell Line | embryonic stem cell |
19 | chr16:76717400-76718000 | Enhancers | iPS-20b Cell Line | embryonic stem cell |
20 | chr16:76717400-76718200 | Enhancers | HUES6 Cell Line | embryonic stem cell |
21 | chr16:76717600-76717800 | Enhancers | H1 Cell Line | embryonic stem cell |
22 | chr16:76717600-76718200 | Enhancers | ES-I3 Cell Line | embryonic stem cell |